If a medication is available in the US but not in your country, read When conventional access fails.
Specialty drug access in Egypt: the named-patient pathway
From first request to drug delivery, a transparent walkthrough of every step.
Last reviewed 2026-05-01 by Reserve Meds clinical & regulatory team. Egypt patients access specialty drugs through a specific regulatory framework documented here.
Why Egypt patients face an access gap in the first place
Egypt has the largest patient population in Reserve Meds' MENA priority countries and a substantial private-sector specialty hospital ecosystem. The Egyptian Drug Authority (EDA) , established in 2019 as an independent regulator separated from the Ministry of Health , handles drug registration and named-patient import. Egypt's high disease burden in oncology (driven historically by hepatitis C-related hepatocellular carcinoma, though HCV prevalence has dropped substantially since the 2014 nationwide treatment campaign) and increasing specialty drug demand have expanded the named-patient pathway's use over the past five years.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Three patterns of access gap apply across Egypt:
- Registered but not stocked. A drug is on the EDA list but a particular hospital pharmacy does not have it on hand.
- Registered for a different indication. A drug is registered for one indication but the physician is prescribing it for another FDA-approved use that is not locally registered.
- Not registered locally at all. A drug is FDA-approved in the United States but the manufacturer has not pursued local registration, often because the patient population is small.
The EDA (Egyptian Drug Authority) named-patient framework
EDA's named-patient framework allows a licensed Egyptian physician to request import of an unregistered medicine for a specific patient. The application is filed through the dispensing pharmacy , typically a private-sector specialty hospital with import infrastructure. EDA reviews clinical justification, prior treatment history, evidence of FDA or EMA approval, manufacturer authorization, and chain-of-custody documentation. The 2019 EDA Law (Law No. 151 of 2019) consolidated regulatory authority and brought formalization to the framework.
The application includes:
- Clinical justification letter (diagnosis, severity, prior therapies, why this specific drug)
- Treating physician's local medical license verification
- Patient identifier (anonymized reference preferred)
- Product details: brand name, generic name, manufacturer, strength, quantity
- Destination dispensing facility license
- Chain-of-custody plan from US source to dispensing pharmacy
We give you a written timeline estimate for your case before you commit.
Egypt's private specialty hospital network
The hospitals that handle named-patient imports as established workflow include: Cleopatra Hospital, As-Salam International Hospital, El-Shorouk Hospital, Cairo Specialized Hospital, Children's Cancer Hospital Egypt 57357 (CCHE 57357), El-Demerdash Cairo University Hospital. These institutions have import pharmacy infrastructure and physicians experienced with framework applications. If your treating physician is at a smaller institution without import infrastructure, we can help coordinate with one of these centers.
Real costs: what Egypt patients actually pay
Costs vary widely by drug. Medicine price: quote on request. You get a written quote for your case before you commit.
Reserve Meds' role shifts from cost optimization to logistical and regulatory orchestration.
Every case gets a written custom quote before you commit, with each line item separated. Nothing is bundled or hidden.
The patient experience: what your family actually does
From the family side, the process looks like this:
- Your physician decides this drug is the right next step. That is a clinical decision and stays with them.
- Your physician (or the hospital's pharmacy team) reaches out to Reserve Meds, or the patient submits the intake request and we connect with the physician.
- We confirm eligibility within one business day and send a documentation kit to your physician.
- Your physician fills out the named-patient application and submits it to EDA.
- While the application processes, Reserve Meds aligns the US-side sourcing and shipment plan.
- Approval comes through. We ship cold-chain (or ambient, depending on the drug). Your hospital pharmacy receives the medicine.
- Your physician initiates therapy.
Common Egypt-specific questions
How does self-pay work for a case from Egypt?
Medicine price: quote on request. You get a written custom quote for your case before you commit. We do not handle currency conversion or local-currency banking.
What if the drug is a controlled substance?
Reserve Meds does not handle controlled substances (DEA Schedule I-V). Controlled-substance imports require separate regulatory coordination beyond the named-patient framework; we refer those cases to specialists.
Can I receive the drug at home or do I need a hospital?
The dispensing facility must be locally licensed. For oral medicines, a hospital outpatient pharmacy or specialized import pharmacy can dispense. For infusion products, the medicine ships to the infusion center where you will receive it. Direct-to-home delivery without a licensed dispensing facility in the chain is not the model.
What about pediatric patients?
The framework applies the same way for pediatric patients. The clinical justification letter typically includes weight-adjusted dosing and pediatric-specific monitoring requirements. The pediatric oncology and rare disease centers in Egypt handle named-patient imports routinely.
Regional context
We give you a written timeline estimate for your case before you commit. The private-sector specialty hospital network , particularly the cluster of private oncology centers in Cairo and Alexandria , handles named-patient cases routinely. Some Egyptian patients with means coordinate care between Egyptian physicians and GCC tertiary centers; Reserve Meds can support both pathways.
Where Reserve Meds fits
Reserve Meds is a US-based digital health company. We do not replace your physician, do not replace EDA, do not replace your dispensing pharmacy. What we do is orchestrate the US-side sourcing, the regulatory documentation kit your physician needs, the international logistics, and a single point of contact throughout your case.
For specialty oncology, rare disease, immunology, neurology, and other specialty therapies, this orchestration is the difference between an unpredictable ad-hoc process and a predictable, documented cycle.
This guide is informational, not medical or legal advice. The named-patient framework requires a licensed Egypt physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.
Drug-access guides for Egypt
Each guide below is a named-patient access pathway for that specific drug in Egypt, with real timelines, written quotes, and the documentation your physician needs. These are coordinated by Reserve Meds for cross-border procurement.